|
1
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2016. CA Cancer J Clin. 66:7–30. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Zheng R, Zeng H, Zhang S and Chen W:
Estimates of cancer incidence and mortality in China, 2013. Chin J
Cancer. 36:662017. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Wolfgang CL, Herman JM, Laheru DA, Klein
AP, Erdek MA, Fishman EK and Hruban RH: Recent progress in
pancreatic cancer. CA Cancer J Clin. 63:318–348. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Ryan DP, Hong TS and Bardeesy N:
Pancreatic adenocarcinoma. N Engl J Med. 371:1039–1049. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Lau MK, Davila JA and Shaib YH: Incidence
and survival of pancreatic head and body and tail cancers: A
population-based study in the United States. Pancreas. 39:458–462.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Borowa-Mazgaj B: Pancreatic
cancer-mechanisms of chemoresistance. Postepy Hig Med Dosw
(Online). 70:169–179. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Semenza GL: Hypoxia-inducible factors:
Mediators of cancer progression and targets for cancer therapy.
Trends Pharmacol. 33:207–214. 2012. View Article : Google Scholar
|
|
8
|
Cosse JP and Michiels C: Tumour hypoxia
affects the responsiveness of cancer cells to chemotherapy and
promotes cancer progression. Anticancer Agents Med Chem. 8:790–797.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Vaupel P, Thews O and Hoeckel M: Treatment
resistance of solid tumors: Role of hypoxia and anemia. Med Oncol.
18:243–259. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Bendinelli P, Maroni P, Matteucci E and
Desiderio MA: Cell and signal components of the microenvironment of
bone metastasis are affected by hypoxia. Int J Mol Sci.
17:E7062016. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Yuen A and Díaz B: The impact of hypoxia
in pancreatic cancer invasion and metastasis. Hypoxia (Auckl).
16:91–106. 2014.
|
|
12
|
Shore GC and Viallet J: Modulating the
bcl-2 family of apoptosis suppressors for potential therapeutic
benefit in cancer. Hematology Am Soc Hematol Educ Program.
2005.226–230. PubMed/NCBI
|
|
13
|
Lin QJ, Yang F, Jin C and Fu DL: Current
status and progress of pancreatic cancer in China. World J
Gastroenterol. 21:7988–8003. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Canel M, Serrels A, Frame MC and Brunton
VG: E-cadherin-integrin crosstalk in cancer invasion and
metastasis. J Cell Sci. 126:393–401. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Satelli A and Li S: Vimentin in cancer and
its potential as a molecular target for cancer therapy. Cell Mol
Life Sci. 68:3033–3046. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Geiger T, Sabanay H, Kravchenko-Balasha N,
Geiger B and Levitzki A: Anomalous features of EMT during
keratinocyte transformation. PLoS One. 3:e15742008. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Kim T, Veronese A, Pichiorri F, Lee TJ,
Jeon YJ, Volinia S, Pineau P, Marchio A, Palatini J, Suh SS, et al:
p53 regulates epithelial-mes-enchymal transition through microRNAs
targeting ZEB1 and ZEB2. J Exp Med. 208:875–883. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Huang S, Okumura K and Sinicrope FA: BH3
mimetic obatoclax enhances TRAIL-mediated apoptosis in human
pancreatic cancer cells. Clin Cancer Res. 15:150–159. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Morgan MA, Meirovitz A, Davis MA, Kollar
LE, Hassan MC and Lawrence TS: Radiotherapy combined with
gemcitabine and oxaliplatin in pancreatic cancer cells. Transl
Oncol. 1:36–43. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Vogel A, Römmler-Zehrer J, Li JS, McGovern
D, Romano A and Stahl M: Efficacy and safety profile of
nab-paclitaxel plus gemcitabine in patients with metastatic
pancreatic cancer treated to disease progression: A subanalysis
from a phase 3 trial MPACT). BMC Cancer. 16:8172016. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Gresham GK, Wells GA, Gill S, Cameron C
and Jonker DJ: Chemotherapy regimens for advanced pancreatic
cancer: A systematic review and network meta-analysis. BMC Cancer.
14:4712014. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Koong AC, Mehta VK, Le QT, Fisher GA,
Terris DJ, Brown JM, Bastidas AJ and Vierra M: Pancreatic tumors
show high levels of hypoxia. Int J Radiat Oncol Biol Phys.
48:919–922. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Guillaumond F, Leca J, Olivares O, Lavaut
MN, Vidal N, Berthezène P, Dusetti NJ, Loncle C, Calvo E, Turrini
O, et al: Strengthened glycolysis under hypoxia supports tumor
symbiosis and hexosamine biosynthesis in pancreatic adenocarcinoma.
Proc Natl Acad Sci USA. 110:3919–3924. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Chang Q, Jurisica I, Do T and Hedley DW:
Hypoxia predicts aggressive growth and spontaneous metastasis
formation from orthotopically grown primary xenografts of human
pancreatic cancer. Cancer Res. 71:3110–3120. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Li YJ, Li L, Liang CQ, Sun XL, Jiang TF
and Ji RX: Expression of hypoxia-inducible factor-1 alpha and
apoptosis and proliferation in pancreatic cancer. Acta Aacademiae
Medical Qingdao Universitatis. 40:11–14. 2004.
|
|
26
|
Schwab LP, Peacock DL, Majumdar D, Ingels
JF, Jensen LC, Smith KD, Cushing RC and Seagroves TN:
Hypoxia-inducible factor 1α promotes primary tumor growth and
tumor-initiating cell activity in breast cancer. Breast Cancer Res.
14:R62012. View
Article : Google Scholar : PubMed/NCBI
|
|
27
|
Copple BL: Hypoxia stimulates hepatocyte
epithelial to mesenchymal transition by hypoxia-inducible factor
and transforming growth factor-β-dependent mechanisms. Liver Int.
30:669–682. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Keane MG, Bramis K, Pereira SP and Fusai
GK: Systematic review of novel ablative methods in locally advanced
pancreatic cancer. World J Gastroenterol. 20:2267–2278. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Rogers CD, Saxena A and Bronner ME: Sip1
mediates an E-cadherin-to-N-cadherin switch during cranial neural
crest EMT. J Cell Biol. 203:835–847. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Díaz-López A, Moreno-Bueno G and Cano A:
Role of microRNA in epithelial to mesenchymal transition and
metastasis and clinical perspectives. Cancer Manag Res. 6:205–216.
2014.PubMed/NCBI
|
|
31
|
Klymenko T, Brandenburg M, Morrow C, Dive
C and Makin G: The novel Bcl-2 inhibitor ABT-737 is more effective
in hypoxia and is able to reverse hypoxia-induced drug resistance
in neuroblastoma cells. Mol Cancer Ther. 10:2373–2383. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Harrison LR, Micha D, Brandenburg M,
Simpson KL, Morrow CJ, Denneny O, Hodgkinson C, Yunus Z, Dempsey C,
Roberts D, et al: Hypoxic human cancer cells are sensitized to BH-3
mimetic-induced apoptosis via downregulation of the Bcl-2 protein
Mcl-1. J Clin Invest. 121:1075–1087. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Gariboldi MB, Taiana E, Bonzi MC,
Craparotta I, Giovannardi S, Mancini M and Monti E: The BH3-mimetic
obatoclax reduces HIF-1α levels and HIF-1 transcriptional activity
and sensitizes hypoxic colon adenocarcinoma cells to
5-fluorouracil. Cancer Lett. 364:156–164. 2015. View Article : Google Scholar : PubMed/NCBI
|
